Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F22%3A00079078" target="_blank" >RIV/00209805:_____/22:00079078 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/22:00128009

Výsledek na webu

<a href="https://sciendo.com/pdf/10.2478/afpuc-2022-0006" target="_blank" >https://sciendo.com/pdf/10.2478/afpuc-2022-0006</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2478/afpuc-2022-0006" target="_blank" >10.2478/afpuc-2022-0006</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience

Popis výsledku v původním jazyce

Autoimmune adverse effects of immune checkpoint inhibitors (ICIs) are rare but may be life-threatening. We performed a retrospective analysis of the immune-related adverse effects (irAEs) of ICIs in the Masaryk Memorial Cancer Institute (MMCI) from 2011 to 2021. The ICIs were administered to 648 patients. Severe irAEs were pronounced in 83 patients (12.8 %). Further, we report a case of severe irAE after treatment with ipilimumab and nivolumab. Prednisone, mesalazine, octreotide, infliximab, vedolizumab, and mycophenolate mofetil were used to manage G4 colitis, with partial response. Early diagnosis and appropriate management of irAE are essential in the perspective of further oncological treatment.

Název v anglickém jazyce

Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience

Popis výsledku anglicky

Autoimmune adverse effects of immune checkpoint inhibitors (ICIs) are rare but may be life-threatening. We performed a retrospective analysis of the immune-related adverse effects (irAEs) of ICIs in the Masaryk Memorial Cancer Institute (MMCI) from 2011 to 2021. The ICIs were administered to 648 patients. Severe irAEs were pronounced in 83 patients (12.8 %). Further, we report a case of severe irAE after treatment with ipilimumab and nivolumab. Prednisone, mesalazine, octreotide, infliximab, vedolizumab, and mycophenolate mofetil were used to manage G4 colitis, with partial response. Early diagnosis and appropriate management of irAE are essential in the perspective of further oncological treatment.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Pharmaceutical Journal

ISSN

2453-6725

e-ISSN

2453-6725

Svazek periodika

69

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

PL - Polská republika

Počet stran výsledku

3

Strana od-do

84-86

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85136909996